Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025

Current state of CAR-T cell therapy for relapsed/refractory ALL in children and young adults.

View Full Paper
Ask AI
Bookmark
Share

Authors

HHHidefumi Hiramatsu

Discussion

Loading...

Member takes

Overview

Review highlights CAR-T cell therapy's impact on relapsed B-ALL in children, suggesting new treatment avenues.

Key Points

  • CAR-T cell therapy shows promise in improving treatment outcomes for relapsed B-ALL in children and young adults.
  • Recent data indicates significant advancements in managing pediatric ALL, particularly with therapies like tisagenlecleucel.
  • This review analyzes strategies for addressing challenges in optimizing post-CAR-T treatment for pediatric patients.
  • The research discusses evolving options for pediatric ALL, with an emphasis on future prospects in CAR-T cell therapy.

Cite This Study

Hidefumi Hiramatsu (2025) studied this question.

synapsesocial.com/papers/68c24236b210217d647a25a5https://doi.org/10.11406/rinketsu.66.673
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Chimeric Antigen Receptor T-cell Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia: Efficacy, Safety, and Future Directions2025 · 1 citations
  2. 2CAR-T Cell Therapies in B-Cell Acute Lymphoblastic Leukemia: Emerging Data and Open Issues2025 · 4 citations
  3. 3CAR-T-Zell-Therapie bei der akuten lymphoblastischen Leukämie2025
  4. 4Efficacy and Safety of CAR T-cell Therapy in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis2025
  5. 5Outcomes with chimeric antigen receptor-t cell therapy in relapsed/refractory b-cell acute lymphoblastic leukemia: A systematic review and meta-analysis2025